In the September 2021 Network Bulletin, we shared a Molecular Pathology Policy update about the use of DEX Z-Codes™ for diagnostic test services. We are pleased to share a newly created FAQ to support the new Z-Code requirement. Read the FAQs.
Background
On Oct. 1, 2021, UnitedHealthcare Medicare Advantage started requiring facility and professional claims in Medicare jurisdictions that have implemented the MolDX program to submit the appropriate DEX Z-Code™ for molecular diagnostic test services.
Laboratories that plan to submit claims for molecular diagnostic testing and are not currently registered with Palmetto’s DEX™ Diagnostics Exchange are urged to sign up today so that claims may be paid.